| First Author | Furth PA | Year | 2023 |
| Journal | Am J Pathol | Volume | 193 |
| Issue | 1 | Pages | 103-120 |
| PubMed ID | 36464513 | Mgi Jnum | J:332257 |
| Mgi Id | MGI:7412387 | Doi | 10.1016/j.ajpath.2022.09.008 |
| Citation | Furth PA, et al. (2023) Overexpression of Estrogen Receptor alpha in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor alpha-Positive Mammary Adenocarcinomas. Am J Pathol 193(1):103-120 |
| abstractText | Age is a risk factor for human estrogen receptor-positive breast cancer, with highest prevalence following menopause. While transcriptome risk profiling is available for human breast cancers, it is not yet developed for prognostication for primary or secondary breast cancer development utilizing at-risk breast tissue. Both estrogen receptor alpha (ER) and aromatase overexpression have been linked to human breast cancer. Herein, conditional genetically engineered mouse models of estrogen receptor 1 (Esr1) and cytochrome P450 family 19 subfamily A member 1 (CYP19A1) were used to show that induction of Esr1 overexpression just before or with reproductive senescence and maintained through age 30 months resulted in significantly higher prevalence of estrogen receptor-positive adenocarcinomas than CYP19A1 overexpression. All adenocarcinomas tested showed high percentages of ER(+) cells. Mammary cancer development was preceded by a persistent proliferative transcriptome risk signature initiated within 1 week of transgene induction that showed parallels to the Prosigna/Prediction Analysis of Microarray 50 human prognostic signature for early-stage human ER(+) breast cancer. CYP19A1 mice also developed ER(+) mammary cancers, but histology was more divided between adenocarcinoma and adenosquamous, with one ER(-) adenocarcinoma. Results demonstrate that, like humans, generation of ER(+) adenocarcinoma in mice was facilitated by aging mice past the age of reproductive senescence. Esr1 overexpression was associated with a proliferative estrogen pathway-linked signature that preceded appearance of ER(+) mammary adenocarcinomas. |
